Findlay Park Partners LLP lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 46.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,336,247 shares of the company’s stock after selling 1,140,000 shares during the quarter. Findlay Park Partners LLP owned approximately 0.27% of Zoetis worth $85,199,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in ZTS. Janus Henderson Group PLC raised its holdings in shares of Zoetis by 7,717.4% during the second quarter. Janus Henderson Group PLC now owns 5,809,086 shares of the company’s stock valued at $362,372,000 after acquiring an additional 5,734,776 shares during the last quarter. Alliancebernstein L.P. raised its holdings in shares of Zoetis by 55.4% during the second quarter. Alliancebernstein L.P. now owns 10,370,388 shares of the company’s stock valued at $646,905,000 after acquiring an additional 3,695,449 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Zoetis by 3.9% during the second quarter. BlackRock Inc. now owns 37,495,299 shares of the company’s stock valued at $2,338,957,000 after acquiring an additional 1,412,829 shares during the last quarter. AJO LP grew its position in shares of Zoetis by 4,506.8% in the second quarter. AJO LP now owns 1,271,425 shares of the company’s stock valued at $79,311,000 after purchasing an additional 1,243,826 shares in the last quarter. Finally, Harbour Capital Advisors LLC grew its position in shares of Zoetis by 6,038.2% in the second quarter. Harbour Capital Advisors LLC now owns 1,227,950 shares of the company’s stock valued at $19,685,000 after purchasing an additional 1,207,945 shares in the last quarter. 93.37% of the stock is owned by institutional investors and hedge funds.
Shares of Zoetis Inc. (NYSE ZTS) traded up $0.95 during trading on Tuesday, reaching $71.90. The company had a trading volume of 1,085,749 shares, compared to its average volume of 2,803,857. The stock has a market capitalization of $34,490.00, a price-to-earnings ratio of 32.47, a price-to-earnings-growth ratio of 2.07 and a beta of 1.02. Zoetis Inc. has a 52 week low of $48.55 and a 52 week high of $71.14. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 9th will be given a $0.105 dividend. The ex-dividend date is Wednesday, November 8th. This represents a $0.42 annualized dividend and a yield of 0.58%. Zoetis’s payout ratio is 22.11%.
ZTS has been the subject of a number of analyst reports. Deutsche Bank AG lowered Zoetis from a “buy” rating to a “hold” rating and set a $65.00 price target for the company. in a research report on Tuesday, July 25th. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and issued a $62.00 price target on shares of Zoetis in a research report on Monday, August 7th. Cantor Fitzgerald set a $75.00 price target on Zoetis and gave the company a “buy” rating in a research report on Monday, August 14th. Cowen and Company set a $70.00 price target on Zoetis and gave the company a “buy” rating in a research report on Thursday, August 24th. Finally, Piper Jaffray Companies set a $73.00 price target on Zoetis and gave the company a “buy” rating in a research report on Friday, August 25th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $67.65.
WARNING: “Zoetis Inc. (ZTS) Shares Sold by Findlay Park Partners LLP” was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/11/21/zoetis-inc-zts-shares-sold-by-findlay-park-partners-llp.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.